We develop tailored biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies.
Our tests support pharmaceutical companies in running successful clinical trials and in maximising access to marketed therapies.
Why Use Biomarkers?
92% of clinical trials fail to gain drug approval
This results in $25bn lost through failed clinical trials annually
Over 99% of neurodegeneration trials are unsuccessful
Enrol the right patients to increase clinical trial success rates 3X
Biomarker tests can optimise patient enrolment into a trial by identifying patients most likely to respond to a drug, dramatically improving chances of statistically significant outcomes
Oncology drugs are ineffective up to 75% of the time, resulting in 6 million deaths annually
This 75% represents over $100bn of drug sales
Uptake of targeted therapies in healthcare settings is restricted by the ability to identify patients reliably
Identify the right patients and improve market access
Biomarker tests can identify patients most likely to respond to targeted therapies, ensuring superior patient outcomes and improved market access
Suboptimal treatment monitoring
Clinical trials are plagued by lengthy endpoints to demonstrate treatment efficacy
Demonstrate treatment efficacy with biomarker endpoints
Biomarker tests measure treatment efficacy on an ongoing basis throughout a clinical trial, increasing efficiency and success rates
Patient Identification & Stratification
Identify & stratify patients to optimise patient enrolment onto clinical trials
Identify patients who will benefit from a therapeutic in healthcare settings with bespoke biomarker tests
Treatment Efficacy Monitoring
Generate robust data demonstrating treatment efficacy to support clinical trials
Why Choose Inoviv?
We use a proprietary technology developed in-house enabling us to measure 50+ fully calibrated molecules per biofluid sample.
This enables us to develop bespoke tests specific to disease subtypes; ideal to support targeted therapies.
Our platform enables us to develop biomarker tests with very high reproducibility and specificity.
We operate from CLIA-certified laboratories in the US and GLP/ GCP labs in the UK.
Our team includes experts from the pharmaceutical industry, clinical practice and academia.
We will work with you to adapt biomarker tests to your needs, depending on the stage of development and the mechanism of action of your therapeutic.
We can analyse 3000 biofluid/ tissue samples per day.
We use our technology platform in combination with mass spectrometry-based targeted proteomics.
Our platform enables high throughput testing of multiplexed protein, peptide, lipid, and metabolite biomarker panels.
Get in Touch
We’re happy to hear from you. Contact us today to learn more about our business and how you can benefit from working with us.
Mappin House, 4 Winsley Street, London W1W 8HF, UK
100 Cambridge Street, Boston, Massachusetts, 02114, USA
+44 117 318 3961